Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bronte-Hall, Lanetta
HIBISCUS, NCT04624659 / 2020-003884-25: A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease	Active, not recruiting	3	450	Europe, Canada, US, RoW	Etavopivat Tablets Low dose, FT-4202, Etavopivat Tablets High dose, Placebo Tablets, placebo, Etavopivat Tablets	Forma Therapeutics, Inc., Novo Nordisk A/S	Sickle Cell Disease	02/26	03/27
NCT05169580: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir	Recruiting	1	70	US, RoW	Pociredir oral capsule(s), FTX-6058	Fulcrum Therapeutics	Sickle Cell Disease, Sickle Cell Anemia	09/25	12/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bronte-Hall, Lanetta
HIBISCUS, NCT04624659 / 2020-003884-25: A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease	Active, not recruiting	3	450	Europe, Canada, US, RoW	Etavopivat Tablets Low dose, FT-4202, Etavopivat Tablets High dose, Placebo Tablets, placebo, Etavopivat Tablets	Forma Therapeutics, Inc., Novo Nordisk A/S	Sickle Cell Disease	02/26	03/27
NCT05169580: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir	Recruiting	1	70	US, RoW	Pociredir oral capsule(s), FTX-6058	Fulcrum Therapeutics	Sickle Cell Disease, Sickle Cell Anemia	09/25	12/25